The food additive includes the following components in weight percent: liquorice—Glycyrrhiza glabra from 1.19% to 47.61%, sweet wormwood—Artemisia annua from 1.19% to 47.61%, quinine bark extract—Cinho from 1.19% to 47.61%, hawthorn extract—Crataegus from 1.19% to 47.61%, dandelion extract—Taraxcum from 1.19% to 47.61%, vitamin C—Ascorbic acid from 1.19% up to 47.61%, DD-Galacturonic acid from 1.19% to 47.61%, apple pectin from 1.19% to 47.61%, bitter orange—Citrus aurantium from 1.19% to 47.61%, ginger—Zingiber officinale from 0.23% to 11.9%, Radix isatidis from 0.23% to 11.9%, Lindera aggregate—0.23% to 11.9%, woad—Isatis indigotica from 0.23% to 9.52%, Torreya nucifera from 0.23% to 9.52%, geranium extract—Pelargonium from 0.23% to 9.52%, Zinc from 0.23% to 2.38% and Sodium Selenite from 0.00119% to 0.04762%.

The present invention relates to a method for treating HIV/AIDS complications including administering a first Chinese herbal medicine composition to a subject in need; wherein the first Chinese herbal medicine composition is an extract of a first mixture including Polygonatum sibiricum, Astragalus membranaceus, Panax ginseng, Liriope spicata, Schisandra chinensis, Ziziphus zizyphus, Cornus officinalis, Fallopia multiflora, and Salvia miltiorrhiza.

The present invention relates to a method for treating HIV/AIDS complications including administering a first Chinese herbal medicine composition to a subject in need; wherein the first Chinese herbal medicine composition is an extract of a first mixture including Polygonatum sibiricum, Astragalus membranaceus, Panax ginseng, Liriope spicata, Schisandra chinensis, Ziziphus zizyphus, Cornus officinalis, Fallopia multiflora, and Salvia miltiorrhiza.

The present invention relates to a method for treating HIV/AIDS complications including administering a first Chinese herbal medicine composition to a subject in need; wherein the first Chinese herbal medicine composition is an extract of a first mixture including Polygonatum sibiricum, Astragalus membranaceus, Panax ginseng, Liriope spicata, Schisandra chinensis, Ziziphus zizyphus, Cornus officinalis, Fallopia multiflora, and Salvia miltiorrhiza.

Disclosed herein are formulations of a poly-herbal synergistic composition which exhibit marked immunomodulatory, anticancer, antiviral and anti-inflammatory properties. Also disclosed are the methods of preparing and using the same.

Disclosed herein are formulations of a poly-herbal synergistic composition which exhibit marked immunomodulatory, anticancer, antiviral and anti-inflammatory properties. Also disclosed are the methods of preparing and using the same.

Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive logP. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.

The present invention relates to a method for producing a liquid composition for oral cavity in which β-glycyrrhetinic acid is stably dispersed or dissolved to exhibit an increased transparency and which also can ensure a sufficient amount of β-glycyrrhetinic acid adsorbed on gingiva, even if the amount of a cationic surfactant or an anionic surfactant is restricted; and such a liquid composition for oral cavity. Specifically, the present invention relates to a method for producing a liquid composition for oral cavity, comprising the following step 1 to step 4: (Step 1) a step of blending water (F) with an organic acid and a salt thereof (E) to adjust the pH of a resultant mixture to 5 or more and 6.8 or less, (Step 2) a step of blending 0.02% by mass or more and 0.1% by mass or less of cetylpyridinium chloride (B) into the mixture, (Step 3) a step of blending 0.02% by mass or more and 0.1% by mass or less of β-glycyrrhetinic acid (A) and 2% by mass or more and 10% by mass or less of propylene glycol (C) into the mixture, and (Step 4) a step of blending 0.45% by mass or more and 1.1% by mass or less of polyoxyethylene hydrogenated castor oil (D) into the mixture, wherein the component (A) and the component (B) are blended at a specific mass ratio, and these steps are carried out in a specific order.

The present invention relates to a method for producing a liquid composition for oral cavity in which β-glycyrrhetinic acid is stably dispersed or dissolved to exhibit an increased transparency and which also can ensure a sufficient amount of β-glycyrrhetinic acid adsorbed on gingiva, even if the amount of a cationic surfactant or an anionic surfactant is restricted; and such a liquid composition for oral cavity. Specifically, the present invention relates to a method for producing a liquid composition for oral cavity, comprising the following step 1 to step 4: (Step 1) a step of blending water (F) with an organic acid and a salt thereof (E) to adjust the pH of a resultant mixture to 5 or more and 6.8 or less, (Step 2) a step of blending 0.02% by mass or more and 0.1% by mass or less of cetylpyridinium chloride (B) into the mixture, (Step 3) a step of blending 0.02% by mass or more and 0.1% by mass or less of β-glycyrrhetinic acid (A) and 2% by mass or more and 10% by mass or less of propylene glycol (C) into the mixture, and (Step 4) a step of blending 0.45% by mass or more and 1.1% by mass or less of polyoxyethylene hydrogenated castor oil (D) into the mixture, wherein the component (A) and the component (B) are blended at a specific mass ratio, and these steps are carried out in a specific order.

The embodiments herein relate to the combination of herbal and probiotic (optionally with prebiotic) treatment for chronic liver diseases to be novel and more effective. Embodiments herein relate to a composition comprising a probiotic and a medicinal herb (and optionally a prebiotic), wherein the composition is effective in treating a liver disease such as inflammation of liver in a novel approach to disease management. The combination of a prebiotic, a probiotic and a medicinal herb constitutes a symbiotic formulation. Clinical and animal data exists to show efficacy of these combinations. The ingredients, as well as the categories, in the combination are novel. Using a combination of twelve herbs and three probiotics, a highly efficacious and novel supplement is disclosed herein. Embodiments of the compositions herein could further include homeopathic drugs and an active pharmaceutical ingredient such as an allopathic drug.